Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 22 points (0.1%) at 16,756 as of Friday, June 13, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,558 issues advancing vs. 1,369 declining with 183 unchanged. The Drugs industry currently sits down 0.4% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Mylan ( MYL), up 1.0%, Actavis ( ACT), up 0.8% and Forest Laboratories ( FRX), up 0.6%. On the negative front, top decliners within the industry include United Therapeutics ( UTHR), down 4.0%, Novo Nordisk A/S ( NVO), down 1.6%, Biomarin Pharmaceutical ( BMRN), down 1.6%, Grifols ( GRFS), down 1.1% and Vertex Pharmaceuticals ( VRTX), down 0.9%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Nektar Therapeutics ( NKTR) is one of the companies pushing the Drugs industry higher today. As of noon trading, Nektar Therapeutics is up $1.62 (12.9%) to $14.16 on heavy volume. Thus far, 2.9 million shares of Nektar Therapeutics exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $13.13-$14.65 after having opened the day at $13.50 as compared to the previous trading day's close of $12.54. Nektar Therapeutics, a clinical-stage biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Nektar Therapeutics has a market cap of $1.6 billion and is part of the health care sector. Shares are up 10.5% year-to-date as of the close of trading on Thursday. Currently there are 6 analysts who rate Nektar Therapeutics a buy, 1 analyst rates it a sell, and 1 rates it a hold. TheStreet Ratings rates Nektar Therapeutics as a sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow. Get the full Nektar Therapeutics Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.